The aim of the Fund is to provide a return by way of capital growth and income.
Name | % Net Assets |
---|---|
United Kingdom Gilt 2.25 07/03/2014 | 2.5% |
United Kingdom Gilt 4 07/09/2016 | 2.3% |
Netherlands Government Bond 4 15/07/2019 | 2.0% |
GlaxoSmithKline PLC | 1.8% |
United Kingdom Gilt 4.5 07/03/2019 | 1.8% |
BP PLC | 1.8% |
Bundesrepublik Deutschland 4.75 04/07/2040 | 1.5% |
Vodafone Group PLC | 1.5% |
HSBC Holdings PLC | 1.4% |
AstraZeneca PLC | 1.3% |
Key | % Net Assets |
---|---|
United Kingdom Gilt 2.25 07/03/2014 | 2.5% |
United Kingdom Gilt 4 07/09/2016 | 2.3% |
Netherlands Government Bond 4 15/07/2019 | 2.0% |
GlaxoSmithKline PLC | 1.8% |
Other | 91.4% |
Date | 09-Apr-2021 |
---|---|
Bid | 132.60p |
Offer | 132.60p |
Currency | GBP |
Change | 0.100p |
% | 0.08% |
YTD change | 132.60p |
YTD % | n/a |
Fund Inception | 16/09/2002 |
---|---|
Fund Manager | Quentin Fitzsimmons |
TER | - |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.10 |
You are here: research